Development and Validation of RP-HPLC Method for Simultaneous Estimation of Terbinafine hydrochloride and Mometasone Furoate in Combined Dosage form

Objective: To develop a validated analytical RP-HPLC method for simultaneous estimation of containing terbinafine hydrochloride and mometasone furoate for pharmaceutical formulation. Method: The sample was estimated using acetonitrile and 0.1% ortho phosphoric acid PH 3 in the ratio 67:33 as mobile phase at a flow rate of 1.0 mL/min and detection at 242 nm. The retention time for terbinafine hydrochloride and mometasone furoate was found to be 2.2 min and 3.5 min respectively. Results and Discussion: The linearity of the developed method was tested in the range of 0.5µg/mL for terbinafine hydrochloride and 1-32µg/mL for mometasone furoate. The limit of detection was 0.0189µg/mL for terbinafine hydrochloride and 0.327µg/mL for mometasone furoate, the % recoveries Was found in the range of 99.98-100.07%. Conclusion: A simple, precise and accurate RP-HPLC method has been developed for the determination of terbinafine hydrochloride and mometasone furoate in pharmaceutical formulations.